Eli Lilly Mounjaro Clocks 65% Jump in Sales to Massive $10.7 billion

Eli Lilly and Co. (NYSE:LLY) shares traded higher Thursday after the drugmaker reported better-than-expected third-quarter results, driven by upbeat demand for its weight loss and diabetes drugs.

Adjusted earnings rose to $7.48 per share, beating the analyst consensus estimate of $6.50.

Revenue increased 39% year over year to $24.397 billion, exceeding the consensus estimate of $22.61 billion.

Third-quarter revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milestones (no further milestones remain) and favorable adjustments to rebate and discount estimates.

The revenue increase was driven by a 53% rise in volume, partly offset by a 15% decline in realized prices.

Mounjaro and Zepbound Sales Drive Core Portfolio Expansion

Key Products revenue rose to $17.1 billion in the quarter, led by Mounjaro and Zepbound.

Worldwide Mounjaro revenue surged 65% to $10.7 billion, and U.S. Zepbound revenue jumped 48% to $5.3 billion, primarily driven by strong demand, partially offset by lower realized prices.

Management Commentary On Global Demand And Manufacturing Investments

“Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook. Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience,” said Chair CEO David Ricks

“To drive durable long-term growth, we continue to invest in our drug-making and technology capabilities, with multiple business development deals and partnerships signed and closed, and with new manufacturing expansions in Texas and Virginia,” Ricks added.

Eli Lilly Raises 2026 Revenue Guidance, Adjusts EPS Targets

Lilly lowered its 2026 adjusted earnings guidance from $35.50-$36.50 per share to $35.00-$36.00 per share, compared with the consensus of $34.04.

The updated earnings guidance reflects acquired IPR&D charges from recent business development activity, including AtaiBeckley and Merida Biosciences.

Lili raised its 2026 sales guidance from $85 billion-$87 billion to $91 billion-$92 billion versus a consensus of $88.848 billion.

LLY Price Action: Eli Lilly shares were trading at $1,388.19 during premarket trading on Thursday. The stock is trading at a new 52-week high, according to Benzinga Pro data.

Image via Shutterstock